摘要
目的:探讨结肠癌激酶4(CCK4)的表达与卵巢癌临床病理特征的关系。方法:采用免疫组织化学MaxVision法检测CCK4在卵巢性索间质肿瘤,卵巢生殖细胞肿瘤、卵巢交界性肿瘤、卵巢上皮性癌组织中的表达。结果:与良性卵巢肿瘤相比,卵巢上皮性癌、卵巢交界性肿瘤、卵巢性索间质肿瘤,卵巢生殖细胞肿瘤明显低表达,差异有统计学意义(P〈0.05)。与卵巢交界性肿瘤相比,卵巢上皮性癌CCK4表达减少,但差异无统计学意义(P〉0.05)。在卵巢上皮性癌中,与年龄〈50岁组相比,年龄≥50组卵巢上皮性癌表达减少,但差异无统计学意义(P〉0.05);与临床分期I-Ⅱ期组相比,临床分期Ⅲ-Ⅳ期组卵巢上皮性癌明显低表达,差异有统计学意义(P〈0.05);与无腹膜转移组相比,有腹膜转移组卵巢上皮性癌明显低表达,差异有统计学意义(P〈0.05)。结论:CCK4低表达与卵巢癌的腹膜转移密切相关,有可能是治疗卵巢癌的重要靶点之一。
Objective: To explore the relationship between the expression of colon cancer kinase - 4 (CCK4) and clinieopathologi- cal characteristics of ovarian cancer. Methods: The expression levels of CCK4 in ovarian sex gonad stromal tumor, ovarian germ cell tumor, borderline ovarian tumor and epithelial ovarian cancer were detected by immunohistochemical MaxVision method. Results: Compared with benign ovarian tumor, the expression levels of CCK4 in epithelial ovarian cancer, borderline ovarian tumor, ovarian sex gonad stromal tumor and ovarian germ cell tumor decreased significantly ( P 〈 0.05 ) . Compared with borderline ovarian tumor, the expression level of CCK4 in epithelial ovarian cancer decreased, but there was no statistically significant difference ( P 〉 0. 05 ) . In epithelial ovarian cancer group, compared with 〈 50 -year- old subgroup, the expression level of CCK4 in ≥50 -year- old subgroup decreased, but there was no statisti- cally significant difference (P 〉0. 05) ; compared with stage Ⅰ - Ⅱ subgroup, the expression level of CCK4 in stage Ⅲ - Ⅳ subgroup de- creased significantly ( P 〈 0.05 ) ; compared with non - peritoneal metastasis subgroup, the expression level of CCK4 in peritoneal metastasis subgroup decreased significantly ( P 〈 0. 05 ) . Conclusion : Downregulation of CCK4 is closely correlated with peritoneal metastasis of ovar- ian cancer, which may be an important target in treatment of ovarian cancer.
出处
《中国妇幼保健》
CAS
北大核心
2014年第12期1940-1942,共3页
Maternal and Child Health Care of China
基金
国家自然青年基金〔81100437〕
江苏省无锡市卫生局科研立项项目〔MD201309〕
关键词
卵巢癌
结肠癌激酶4
免疫组织化学
腹膜转移
Ovarian cancer
Colon cancer kinase -4
Immunohistochemistry
Peritoneal metastasis